These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2122251)

  • 1. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
    Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
    N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
    Thompson PL; Aylward PE; Federman J; Giles RW; Harris PJ; Hodge RL; Nelson GI; Thomson A; Tonkin AM; Walsh WF
    Circulation; 1991 May; 83(5):1534-42. PubMed ID: 1902404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
    Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
    Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
    Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    TIMI Study Group
    N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
    Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
    Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
    Van de Werf F; Arnold AE
    BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    Malcolm AD; Keltai M; Walsh MJ
    Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
    Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
    Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
    J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
    Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
    Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
    Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
    J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
    Verstraete M; Arnold AE; Brower RW; Collen D; de Bono DP; De Zwaan C; Erbel R; Hillis WS; Lennane RJ; Lubsen J
    Am J Cardiol; 1987 Aug; 60(4):231-7. PubMed ID: 3113222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
    Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
    Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.